Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$22.80
+2.7%
$23.81
$20.84
$34.28
$2.37B0.481.47 million shs795,534 shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$13.47
-3.2%
$15.07
$6.46
$35.67
$2.08B2.34.11 million shs2.84 million shs
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
$3.93
-3.2%
$6.09
$1.87
$40.58
$277.07M0.273.60 million shs529,055 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$40.50
+1.0%
$43.95
$27.99
$50.99
$3.05B1.15398,124 shs320,772 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
+2.66%-0.65%-9.95%+5.26%+2.56%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
-3.16%-2.25%-13.49%-14.75%-39.05%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-3.20%-12.08%-32.30%+92.65%-89.28%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+1.00%+1.55%-5.81%-11.26%+2.48%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
4.8166 of 5 stars
3.51.00.04.53.03.33.1
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
3.7118 of 5 stars
4.40.00.03.51.21.70.6
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
3.3918 of 5 stars
3.34.00.00.01.74.21.3
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.6436 of 5 stars
3.54.00.00.02.62.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
3.00
Buy$39.3072.37% Upside
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.83
Moderate Buy$29.00115.29% Upside
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
2.56
Moderate Buy$21.75453.44% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$59.4446.78% Upside

Current Analyst Ratings

Latest XENE, TGTX, CORT, and VTYX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00
4/18/2024
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$39.00
4/18/2024
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00
4/18/2024
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00
4/12/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$62.00
4/10/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$65.00
3/13/2024
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
3/12/2024
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$12.00
3/12/2024
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$7.00 ➝ $16.00
3/1/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$56.00 ➝ $55.00
3/1/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$46.00 ➝ $51.00
(Data available from 4/27/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$482.38M4.92$0.97 per share23.47$4.92 per share4.63
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$233.66M8.91$0.08 per share159.91$1.06 per share12.71
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/A$4.13 per shareN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$9.43M323.96N/AN/A$14.18 per share2.86

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$106.14M$0.9524.0017.14N/A21.86%21.98%17.89%5/1/2024 (Confirmed)
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$12.67M$0.02673.8423.22N/A5.42%12.89%4.70%5/6/2024 (Estimated)
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$192.96M-$3.30N/AN/AN/AN/A-62.58%-57.42%5/9/2024 (Estimated)
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$182.39M-$2.72N/AN/AN/AN/A-25.18%-23.99%5/14/2024 (Estimated)

Latest XENE, TGTX, CORT, and VTYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.18N/A-$0.18N/AN/AN/A  
2/29/2024Q4 2023
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$0.76-$0.64+$0.12-$0.64$2.30 millionN/A    
2/28/2024Q4 2023
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
-$0.12-$0.09+$0.03-$0.09$40.06 million$43.97 million    
2/27/2024Q4 2023
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$0.87-$0.79+$0.08-$0.79N/AN/A
2/15/2024Q4 2023
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.25$0.28+$0.03$0.28$129.27 million$135.41 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
4.39
4.31
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
0.62
5.92
5.18
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/A
11.87
11.87
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
23.65
23.65

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
97.88%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
19.80%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
9.20%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
24.39%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
5.43%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
352104.08 million83.48 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
264154.54 million140.33 millionOptionable
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
7970.50 million53.30 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
25175.43 million71.34 millionOptionable

XENE, TGTX, CORT, and VTYX Headlines

SourceHeadline
Jennison Associates LLC Buys 352,573 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Jennison Associates LLC Buys 352,573 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
marketbeat.com - April 25 at 7:27 AM
Federated Hermes Inc. Invests $15.96 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Federated Hermes Inc. Invests $15.96 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
marketbeat.com - April 23 at 5:35 AM
Investors Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)Investors Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)
americanbankingnews.com - April 18 at 3:04 AM
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual MeetingXenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
globenewswire.com - April 16 at 8:30 AM
Needham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)Needham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
marketbeat.com - April 12 at 8:14 AM
Xenon Pharmaceuticals Inc (XENE)Xenon Pharmaceuticals Inc (XENE)
investing.com - April 10 at 12:10 PM
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
globenewswire.com - April 10 at 8:30 AM
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare ConferenceXenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
globenewswire.com - April 4 at 4:01 PM
SG Americas Securities LLC Sells 38,146 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)SG Americas Securities LLC Sells 38,146 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
marketbeat.com - April 2 at 4:18 AM
Assenagon Asset Management S.A. Sells 47,962 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Assenagon Asset Management S.A. Sells 47,962 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
marketbeat.com - April 1 at 4:43 AM
Xenon Pharmaceuticals IncXenon Pharmaceuticals Inc
money.usnews.com - March 21 at 10:13 AM
Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth PlansXenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - March 19 at 8:26 AM
XENE Apr 2024 47.500 putXENE Apr 2024 47.500 put
finance.yahoo.com - March 16 at 1:48 PM
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS DaysXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
globenewswire.com - March 12 at 4:01 PM
Insider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells 7,137 Shares of StockInsider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells 7,137 Shares of Stock
insidertrades.com - March 11 at 6:41 AM
Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...
finance.yahoo.com - March 9 at 12:06 AM
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
globenewswire.com - March 5 at 4:01 PM
Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline ProgressBuy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress
markets.businessinsider.com - March 5 at 10:33 AM
Xenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call TranscriptXenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 2 at 2:52 PM
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call TranscriptXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 2 at 9:52 AM
Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - March 1 at 2:30 PM
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in FocusXenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
zacks.com - March 1 at 9:36 AM
Buy Rating Justified by Xenon Pharmaceuticals’ Advanced Epilepsy Program and Growth Prospects in NeuroscienceBuy Rating Justified by Xenon Pharmaceuticals’ Advanced Epilepsy Program and Growth Prospects in Neuroscience
markets.businessinsider.com - March 1 at 9:23 AM
Xenon Pharmaceuticals Inc (XENE) Reports Full Year and Q4 2023 Financial ResultsXenon Pharmaceuticals Inc (XENE) Reports Full Year and Q4 2023 Financial Results
finance.yahoo.com - February 29 at 7:35 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Corcept Therapeutics logo

Corcept Therapeutics

NASDAQ:CORT
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
TG Therapeutics logo

TG Therapeutics

NASDAQ:TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Ventyx Biosciences logo

Ventyx Biosciences

NASDAQ:VTYX
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Xenon Pharmaceuticals logo

Xenon Pharmaceuticals

NASDAQ:XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.